@article{9506812d2bff483cbae1496509de8718,
title = "ACTIVE POST-MARKETING SAFETY SURVEILLANCE OF NIRSEVIMAB ADMINISTERED TO CHILDREN IN WESTERN AUSTRALIA, APRIL-JULY 2024",
abstract = "Children receiving nirsevimab were texted a link to an online survey to monitor adverse events following immunization. Total of 4340 parents received the link, which 1195 (27.5%) responded. Forty-seven (11.4%) of 410 children who received nirsevimab alone and 230 (29.3%) of 785 children who received nirsevimab coadministered reported any reaction. No adverse events required in-patient care or had ongoing sequelae.",
keywords = "adverse events following immunization, Beyfortus, nirsevimab, respiratory syncytial virus, vaccine safety",
author = "Dale Carcione and Phoebe Spencer and Grace Pettigrew and Alan Leeb and Carla Drake-Brockman and Timothy Ford and Paul Effler",
note = "Publisher Copyright: Copyright {\textcopyright} 2025 Wolters Kluwer Health, Inc. All rights reserved.",
year = "2025",
month = jan,
day = "3",
doi = "10.1097/INF.0000000000004715",
language = "English",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams & Wilkins",
}
